# OnCo record idea-prostate-hrr-testing-at-metastatic-diagnosis (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-prostate-hrr-testing-at-metastatic-diagnosis" ;
  schema:name "Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later"@en ;
  schema:alternateName "HRR testing at metastatic diagnosis"@en, "germline and tumour DNA repair testing timing prostate"@en ;
  schema:description "About one man in eight with prostate cancer that has spread carries an inherited DNA repair fault, and about one in five has one in the tumour. The drugs for those faults have moved to the beginning of treatment, but the test is still usually done near the end, when it is too late to use the result."@en ;
  schema:url <https://onco.cc/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  onco:tag "prostate-evidence" ;
  onco:related <https://onco.cc/ideas/idea-prev-reflex-germline-testing/>, <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/roadmaps/targeted-therapy-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-nmcrpc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/prevention/> ;
  onco:technologies <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/cdk12/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/myriad-genetics/>, <https://onco.cc/companies/foundation-medicine/> ;
  onco:terms <https://onco.cc/terms/genome-wide-loss-of-heterozygosity/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-care-fragmentation/>, <https://onco.cc/bottlenecks/b-knowledge-diffusion/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/>, <https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/>, <https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/>, <https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/>, <https://onco.cc/key-papers/paper-nct04821622-n-engl-j-med-2026/> .